How many clinical trials are studying Pemetrexed Disodium?

3 recruiting trials in our tracked data involve Pemetrexed Disodium.

What conditions is Pemetrexed Disodium being studied for?

In our tracked recruiting trials, Pemetrexed Disodium is being studied in trials for Lung cancer, Lung Cancer, Non-Small Cell, Lung Non-Small Cell Carcinoma.

Pemetrexed Disodium: clinical trials recruiting now

Q: Is Pemetrexed Disodium FDA-approved?

Yes. According to the FDA drug label available through openFDA, Pemetrexed Disodium is an FDA-approved drug.

Recruiting trials

Conditions studied

US states with sites

Countries

FDA drug label

FDA-approved: Yes. Pemetrexed Disodium appears in the FDA drug-label database. Marketed as Pemetrexed.

FDA-approved use

Pemetrexed for injection is a folate analog metabolic inhibitor indicated: in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations. ( 1.1 ) in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic, non-squamous NSCLC. ( 1.1 ) as a single agent for the maintenance treatment of patients with locally advanced or metastatic, non-squamous NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. ( 1.1 ) as a single agent for the treatment of patients with recurrent, metastatic non-squamous, NSCLC after prior chemotherapy. ( 1.1 ) Limitations of Use: Pemetrexed for injection is not indicated for the treatment of patients with squamous cell, non-small cell lung cancer. ( 1.1 ) initial treatment, in combination with cisplatin, of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery. ( 1.2 ) 1.1 Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Pemetrexed for Injection is indi…

FDA recalls / enforcement

Reason (FDA)	Classification	Status	Initiated
Discolored solution. The firm has received market complaints reporting green to dark green discoloration in certain vials — Shilpa Medicare Limited	Class II (FDA: may cause temporary or reversible harm)	Ongoing	2026-07-29
Discolored solution. The firm has received market complaints reporting green to dark green discoloration in certain vials — Shilpa Medicare Limited	Class II (FDA: may cause temporary or reversible harm)	Ongoing	2026-07-29

FDA label via openFDA

Phase breakdown

Phase 2 2 Phase 3 1

Conditions being studied

Condition	Trials
Lung cancer · Pemetrexed Disodium for Lung cancer	3
Lung Cancer, Non-Small Cell	1
Lung Non-Small Cell Carcinoma	1
Lung Non-Small Cell Squamous Carcinoma	1
Lung Non-Squamous Non-Small Cell Carcinoma	1
Nasopharyngeal Carcinoma	1
Non-small Cell Lung Cancer	1
Solid Tumor	1
Stage II Lung Cancer AJCC v8	1
Stage IIIA Lung Cancer AJCC v8	1
Stage IIIB Lung Cancer AJCC v8	1

Recruiting trials involving Pemetrexed Disodium

A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
NCT06475300 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
Perioperative Tislelizumab for Resectable II-IIIB(N2) KRAS-mutated Nonsquamous Non-small Cell Lung Cancer
NCT06659042 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
NCT04267848 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1151 locations

Common questions

Is Pemetrexed Disodium FDA-approved?

Yes, marketed as Pemetrexed.

How many recruiting trials involve Pemetrexed Disodium?

3 recruiting trials across 11 conditions.

Is this list of trials complete?

No. For the full record, search ClinicalTrials.gov.